Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

被引：204

作者：

Artale, Salvatore ^{[1
]}

Sartore-Bianchi, Andrea ^{[1
]}

Veronese, Silvio Marco ^{[2
]}

Gambi, Valentina ^{[1
]}

Sarnataro, Carolina Silvia ^{[1
]}

Gambacorta, Marcello ^{[2
]}

Lauricella, Calogero ^{[2
]}

Siena, Salvatore ^{[1
]}

机构：

[1] Osped Niguarda Granda, Falck Div Med Oncol, Milan, Italy

[2] Osped Niguarda Granda, Div Pathol, Milan, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 25期

关键词：

D O I：

10.1200/JCO.2008.18.7286

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：4217 / 4219

页数：4

共 15 条

[1]

Al-Mulla F, 1998, J PATHOL, V185, P130, DOI 10.1002/(SICI)1096-9896(199806)185:2<130::AID-PATH85>3.0.CO

[2]

2-M

[3] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[4]

[Anonymous], 2008, Journal of Clinical Oncology

[5] Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].

Benvenuti, Silvia ;

Sartore-Bianchi, Andrea ;

Di Nicolantonio, Federica ;

Zanon, Carlo ;

Moroni, Mauro ;

Veronese, Silvio ;

Siena, Salvatore ;

Bardelli, Alberto .

CANCER RESEARCH, 2007, 67 (06) :2643-2648

[6] Bleomycin in testicular cancer: Will pharmacogenomics improve treatment regimens? [J].

Bokemeyer, Carsten .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) :1783-1785

[7] Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy [J].

Di Fiore, F. ;

Blanchard, F. ;

Charbonnier, F. ;

Le Pessot, F. ;

Lamy, A. ;

Galais, M. P. ;

Bastit, L. ;

Killian, A. ;

Sesboue, R. ;

Tuech, J. J. ;

Queuniet, A. M. ;

Paillot, B. ;

Sabourin, J. C. ;

Michot, F. ;

Michel, P. ;

Frebourg, T. .

BRITISH JOURNAL OF CANCER, 2007, 96 (08) :1166-1169

[8]

European Medicines Agency, QUEST ANSW MARK AUTH

[9] Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab [J].

Khambata-Ford, Shirin ;

Garrett, Christopher R. ;

Meropol, Neal J. ;

Basik, Mark ;

Harbison, Christopher T. ;

Wu, Shujian ;

Wong, Tai W. ;

Huang, Xin ;

Takimoto, Chris H. ;

Godwin, Andrew K. ;

Tan, Benjamin R. ;

Krishnamurthi, Smitha S. ;

Burris, Howard A., III ;

Poplin, Elizabeth A. ;

Hidalgo, Manuel ;

Baselga, Jose ;

Clark, Edwin A. ;

Mauro, David J. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) :3230-3237

[10] KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab [J].

Lievre, Astrid ;

Bachet, Jean-Baptiste ;

Boige, Valerie ;

Cayre, Anne ;

Le Corre, Delphine ;

Buc, Emmanuel ;

Ychou, Marc ;

Bouche, Olivier ;

Landi, Bruno ;

Louvet, Christophe ;

Andre, Thierry ;

Bibeau, Frederic ;

Diebold, Marie-Daniele ;

Rougier, Philippe ;

Ducreux, Michel ;

Tomasic, Gorana ;

Emile, Jean-Francois ;

Penault-Llorca, Frederique ;

Laurent-Puig, Pierre .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :374-379

← 1 2 →